Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
LEVONORGESTREL (UNII: 5W7SIA7YZW) (LEVONORGESTREL - UNII:5W7SIA7YZW), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)
Amneal Pharmaceuticals NY LLC
LEVONORGESTREL
LEVONORGESTREL 0.15 mg
PRESCRIPTION DRUG
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and the IUD, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF USE OF A CONTRACEPTIVE METHOD Method Perfect Use Typical Use Levonorgestrel implants 0.05 0.05 Male sterilization 0.1 0.15 Female sterilization 0.5 0.5 Depo-Provera® (injectable progestogen) 0.3 0.3 Oral contraceptives 5 Combined 0.1 NA Progestin only 0.5 NA IUD Progesterone 1.5 2 Copper T 380A 0.6 0.8 Condom (male) without spermicide 3 14 (Female) without spermicide 5 21 Cervical cap Nulliparous women 9 20 Par
Lillow® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) are available as follows: NDC 69238-1554-6 Blister Pack of 28 Tablets 21 active tablets - white, round, biconvex, film-coated tablet, debossed with ‘C5’ on one side. 7 inert tablets - yellow, round, biconvex, film-coated tablet, debossed with ‘C2’ on one side. Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. References available upon request. Made in Germany Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 08-2017-03
Abbreviated New Drug Application
LILLOW- LEVONORGESTREL AND ETHINYL ESTRADIOL AMNEAL PHARMACEUTICALS NY LLC ---------- LILLOW (LEVONORGESTREL AND ETHINYL ESTRADIOL TABLETS, USP) 0.15 MG/0.03 MG RX ONLY PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES. DESCRIPTION 21 white Lillow tablets, each containing 0.15 mg of levonorgestrel, USP, (d(-)-13 beta- ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one), a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol, USP, (19-nor-17α-pregna-1,3,5 (10)-trien-20-yne-3,17- diol), and 7 yellow inert tablets. The inactive ingredients present in both tablets are lactose monohydrate, magnesium stearate, microcrystalline cellulose, and polacrilin potassium. White tablets are coated with Aqua Polish White 014.17 MS which contains hydrogenated cottonseed oil, hydroxypropylcellulose, hydroxypropylmethylcellulose, talc and titanium dioxide. Yellow inert tablets are coated with Aqua Polish Yellow 024.15 MS which contains hydrogenated cottonseed oil, hydroxypropylcellulose, hydroxypropylmethylcellulose, ferric oxide red, ferric oxide yellow, talc, and titanium dioxide. ® ® CLINICAL PHARMACOLOGY Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). INDICATIONS AND USAGE Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and the IUD, depends The efficacy of these contraceptive methods, except sterilization and the IUD, depends upon th Lue koko asiakirja